Nanobiotix Reports Full Year 2025 Results, Strengthens Financial Position
Biotechnology firm Nanobiotix released its full-year 2025 financial results and provided an operational update, strengthening its financial standing through royalty financing and licensing agreement amendments.
PARIS and CAMBRIDGE, Massachusetts – March 31, 2026 – Nanobiotix, a late-stage clinical biotechnology company focused on nanotherapeutics for cancer, announced its full-year 2025 financial results and provided an update on its operational progress. The company bolstered its financial position significantly by closing a royalty financing deal worth up to $71 million with HealthCare Royalty and amending its global licensing agreement for JNJ-1900 (NBTXR3).
The global development program for Nanobiotix's JNJ-1900 (NBTXR3) is proceeding as planned, with lead programs targeting head and neck cancer and lung cancer. The company reported promising clinical results across multiple tumor types, including esophageal cancer, pancreatic cancer, melanoma, and head and neck and lung cancers. These findings support the broad potential of JNJ-1900 (NBTXR3) in solid tumors treated with radiotherapy.
Advancements were also made in the Curadigm Nanoprimer platform, with the filing of four new patent applications and the presentation of new in vivo data. External collaboration momentum is building, and Chemistry, Manufacturing, and Controls (CMC) activities are underway to support both internal and external pipelines.
Financially, Nanobiotix ended 2025 with €52.8 million in cash and cash equivalents, extending its cash runway into early 2028. Clinical data readouts are expected in 2026 from studies related to non-small cell lung cancer (re-irradiation), pancreatic cancer, melanoma, and esophageal cancer.